FIELD: biotechnology.
SUBSTANCE: anti-HLA-G antibody, method for its production and use for cancer treatment are presented. Also an isolated nucleic acid encoding an antibody, a host cell designed to produce the antibody, and a pharmaceutical composition for the treatment of cancer are provided.
EFFECT: invention makes it possible to obtain new antibodies with high affinity for HLA-G.
13 cl, 11 dwg, 13 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 | 2018 |
|
RU2778805C2 |
| ANTIBODIES TO LAG3 | 2018 |
|
RU2778053C2 |
| ANTIBODIES AGAINST SIGNAL-REGULATORY ALPHA PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2771964C2 |
| ANTIBODIES TO DENGUE VIRUS, POLYPEPTIDES CONTAINING FC-REGION OPTIONS AND THEIR APPLICATION METHODS | 2017 |
|
RU2758596C2 |
| PD1 ANTIBODIES AND THEIR APPLICATION METHODS | 2016 |
|
RU2746409C1 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF THEIR USE | 2019 |
|
RU2800779C2 |
| MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING SUBSTITUTE FUNCTIONAL ACTIVITY OF BLOOD COAGULATING FACTOR VIII CO-FACTOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SPECIFIED MOLECULE AS ACTIVE INGREDIENT | 2018 |
|
RU2812909C2 |
| ANTI-TAU PROTEIN ANTIBODIES AND METHODS OF USING SAID ANTIBODIES | 2016 |
|
RU2732122C2 |
| ANTIBODIES TO DENGUE VIRUS WITH CROSS-REACTIVITY WITH ZIKA VIRUS | 2019 |
|
RU2811697C2 |
| ANTIBODIES TO MYOSTATIN, POLYPEPTIDES CONTAINING FC-REGION VARIANTS, AND THEIR APPLICATION METHODS | 2016 |
|
RU2789884C2 |
